CB-103 has been granted an Orphan Designation for the treatment of Acute Lymphoblastic Leukaemia (ALL)

Cellestia Biotech AG announces that the European Commission (EC) has granted CB-103 an orphan designation for the treatment of Acute Lymphoblastic Leukaemia (ALL).

This is the first Orphan Designation granted to CB-103. It is an important milestone in the development of CB-103, as it represents an official recognition from EMA that CB-103 looks promising in bringing significant benefit to those affected by ALL.

To read the Press Release click here